170 related articles for article (PubMed ID: 34663310)
21. Circular RNA circCSPP1 knockdown attenuates doxorubicin resistance and suppresses tumor progression of colorectal cancer via miR-944/FZD7 axis.
Xi L; Liu Q; Zhang W; Luo L; Song J; Liu R; Wei S; Wang Y
Cancer Cell Int; 2021 Mar; 21(1):153. PubMed ID: 33663510
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
23. MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc.
Tao L; Shu-Ling W; Jing-Bo H; Ying Z; Rong H; Xiang-Qun L; Wen-Jie C; Lin-Fu Z
Biomed Pharmacother; 2020 May; 125():109962. PubMed ID: 32106373
[TBL] [Abstract][Full Text] [Related]
24. Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer.
Qian Y; Bi L; Yang Y; Wang D
Anticancer Drugs; 2018 Aug; 29(7):616-627. PubMed ID: 29782350
[TBL] [Abstract][Full Text] [Related]
25. MiR-202-5p/
Liu T; Guo J; Zhang X
Cancer Biol Ther; 2019; 20(7):989-998. PubMed ID: 30983514
[TBL] [Abstract][Full Text] [Related]
26. miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells.
Hu SH; Wang CH; Huang ZJ; Liu F; Xu CW; Li XL; Chen GQ
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(23):5002-5008. PubMed ID: 27981531
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
28. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin resistance in breast cancer is mediated via the activation of FABP5/PPARĪ³ and CaMKII signaling pathway.
Chen NN; Ma XD; Miao Z; Zhang XM; Han BY; Almaamari AA; Huang JM; Chen XY; Liu YJ; Su SW
Front Pharmacol; 2023; 14():1150861. PubMed ID: 37538178
[TBL] [Abstract][Full Text] [Related]
30. MiR-212-5p inhibits the malignant behavior of clear cell renal cell carcinoma cells by targeting TBX15.
Deng JH; Zheng GY; Li HZ; Ji ZG
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10699-10707. PubMed ID: 31858538
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
Sun FD; Wang PC; Luan RL; Zou SH; Du X
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
[TBL] [Abstract][Full Text] [Related]
32. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
[TBL] [Abstract][Full Text] [Related]
33. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
34. MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression.
Zheng Y; Lv X; Wang X; Wang B; Shao X; Huang Y; Shi L; Chen Z; Huang J; Huang P
Oncol Rep; 2016 Feb; 35(2):683-90. PubMed ID: 26572075
[TBL] [Abstract][Full Text] [Related]
35. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
36. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
37. miR-27b-3p is Involved in Doxorubicin Resistance of Human Anaplastic Thyroid Cancer Cells via Targeting Peroxisome Proliferator-Activated Receptor Gamma.
Xu Y; Han YF; Ye B; Zhang YL; Dong JD; Zhu SJ; Chen J
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):670-677. PubMed ID: 29924913
[TBL] [Abstract][Full Text] [Related]
38. miR-361-5p modulates metabolism and autophagy via the Sp1-mediated regulation of PKM2 in prostate cancer.
Ling Z; Liu D; Zhang G; Liang Q; Xiang P; Xu Y; Han C; Tao T
Oncol Rep; 2017 Sep; 38(3):1621-1628. PubMed ID: 29094170
[TBL] [Abstract][Full Text] [Related]
39. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
Wang B; Xu L; Zhang J; Cheng X; Xu Q; Wang J; Mao F
Biomed Pharmacother; 2020 Sep; 129():110268. PubMed ID: 32563146
[TBL] [Abstract][Full Text] [Related]
40. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.
Chen J; Yu Y; Chen X; He Y; Hu Q; Li H; Han Q; Ren F; Li J; Li C; Bao J; Ren Z; Duan Z; Cui G; Sun R
Cell Prolif; 2018 Dec; 51(6):e12510. PubMed ID: 30105813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
